

Technology Advisory Interests Register

Topic: Acalabrutinib with bendamustine and rituximab for untreated mantle cell lymphoma [ID6155]

Publication Date: TBC

Name	Role with NICE	Type of interest	Description of interest	Interest declared	Comments
Kate Ren	TAC Committee Member	Financial	I provided statistical methodology consultancy service to a possible comparator company Pfizer for an unrelated treatment in an unrelated disease area (Tofacitinib for Moderate-to-Severe Ulcerative Colitis).	08/01/2026	It was agreed that Kate's declaration would not prevent them from participating in discussions on this appraisal
Mike Chambers	TAC Committee Member	Financial	I have participated in an advisory panel for Pfizer (possible comparator company) in an unrelated disease area - prostate cancer, and in an advisory board for Accord (possible comparator company) in an unrelated disease area - small-cell lung cancer.	08/01/2026	It was agreed that Mike's declaration would not prevent them from participating in discussions on this appraisal
Elizabeth Thurgar	TAC Committee Member	Financial	I am currently working with Pfizer in an unrelated indication, non-small cell lung cancer.	08/01/2026	It was agreed that Elizabeth's declaration would not prevent them from participating in discussions on this appraisal

Name	Role with NICE	Type of interest	Description of interest	Interest declared	Comments
Jonathan Sive	TAC Committee Member	Financial	I was sponsored to attend in educational meeting by J&J last year.	09/01/2026	It was agreed that Jonathan's declaration would not prevent them from participating in discussions on this appraisal
Pedro Saramago Goncalves	TAC Committee Member	Financial	I would like to declare that in the last 12 months I have worked with Vantive (a company previously owned by Baxter, which has a potential comparator for this technology appraisal) but in an unrelated indication - medical device for pulmonary ventilation. Also, I would like to declare that in the last 12 months I have worked with J&J (another company with a potential comparator for this appraisal) on a project evaluating US FDA Accelerated Approvals process i.e. non-technology specific.	10/01/2026	It was agreed that Pedro's declaration would not prevent them from participating in discussions on this appraisal
Dr Rory McCulloch	Expert	Direct - financial	Previous payments received from AstraZeneca: advisory board September 2024: £1899.80 advisory board July 2025: £1215.00	31/01/2026	It was agreed that Dr McCulloch's declaration would not prevent them from providing expert advice to the committee

Name	Role with NICE	Type of interest	Description of interest	Interest declared	Comments
			AstraZeneca: £5166 for advisory board activity (4 different events), and sponsored attendance at the European Haematology Association in June 2024.	31/03/2025	